key: cord-0944370-l97yi8l9
authors: Ahmed, Sabeena; Karim, Mohammad Mahbubul; Ross, Allen G.; Hossain, Mohammad Sharif; Clemens, John D.; Sumiya, Mariya Kibtiya; Phru, Ching Swe; Rahman, Mustafizur; Zaman, Khalequ; Somani, Jyoti; Yasmin, Rubina; Hasnat, Mohammad Abul; Kabir, Ahmedul; Aziz, Asma Binte; Khan, Wasif Ali
title: A five day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness
date: 2020-12-02
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2020.11.191
sha: 683e72c792dbf51e156a59db698c18e702919f5a
doc_id: 944370
cord_uid: l97yi8l9

Ivermectin, an FDA-approved anti-parasitic agent, was found in vitro to inhibit SARS-CoV-2 replication. To determine the rapidity of viral clearance and safety of ivermectin among adult SARS-CoV-2 patients we conducted a randomized, double-blind, placebo-controlled trial of oral ivermectin alone (12 mg once daily for 5 days) or in combination with doxycycline (12 mg ivermectin single dose and 200 mg stat doxycycline day-1 followed by 100 mg 12hrly for next 4 days) compared with placebo among 72 hospitalized patients in Dhaka, Bangladesh. Clinical symptoms of fever, cough and sore throat were comparable among the three treatment arms. Virological clearance was earlier in the 5-day ivermectin treatment arm versus the placebo group (9.7 days vs. 12.7 days; P = 0.02); but not with the ivermectin + doxycycline arm (11.5 days; P = 0.27). There were no severe adverse drug events recorded in the study. A 5-day course of ivermectin was found to be safe and effective in treating mild COVID-19 adult patients. Larger trials will be needed to confirm these preliminary findings.

• Remission of fever, cough and sore throat did not differ between those treated with or without ivermectin. No severe adverse event observed with the longer duration of ivermectin use.

• Larger trials will be needed to confirm these preliminary findings.

Ivermectin, an FDA-approved anti-parasitic agent, was found in vitro to inhibit SARS-CoV-2

replication. To determine the rapidity of viral clearance and safety of ivermectin among adult SARS-CoV-2 patients we conducted a randomized, double-blind, placebo-controlled trial of oral ivermectin alone (12mg once daily for 5 days) or in combination with doxycycline (12mg ivermectin single dose and 200mg stat doxycycline day-1 followed by 100mg 12hrly for next 4 days) compared with placebo among 72 hospitalized patients in Dhaka, Bangladesh. Clinical symptoms of fever, cough and sore throat were comparable among the three treatment arms.

Virological clearance was earlier in the 5-day ivermectin treatment arm versus the placebo group (9.7 days vs. 12.7 days; P =0.02); but not with the ivermectin + doxycycline arm (11.5 days;

Introduction COVID-19, caused by the novel Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2), has become a global pandemic of the highest priority. 1 Eighty-one percent of the cases are categorized as mild for whom symptomatic management at home and monitoring of clinical deterioration is recommended. 2 Despite providing symptomatic management, a therapeutic drug that would limit the course of infection is greatly needed.

Ivermectin, a popular anti-parasitic drug, acts on SARS-CoV-2 by preventing viral proteins from entering the host cell nucleus. 3 Recent virtual drug screening identified doxycycline as a potential inhibitor of SARS-CoV-2 papain-like protease. 4 An observational study with a single-dose of ivermectin with a multi-dose of doxycycline for the treatment of COVID-19 yielded considerable improvement of symptoms and viral response. 5 A recent retrospective study found that hospitalized patients given ivermectin with other treatments (e.g., azithromycin and hydroxychloroquine) had a lower mortality than those who did not receive ivermectin. 6 Further studies are needed to verify these findings. This need is further underscored by the observations that SARS-CoV-2 rapidly multiplies in the respiratory tract and that evidence from animal models shows 3-fold higher levels of ivermectin in pulmonary tissue than in the plasma one

week after oral dosing. 7, 8 In this pilot study we evaluated the rapidity of viral clearance and safety of a 5-day course of ivermectin or a single-dose of ivermectin with a 5-day course of doxycycline in the treatment of mild COVID-19 in adults.

To determine the rapidity of viral clearance and safety of ivermectin among adult SARS-CoV-2 patients we conducted a randomized, double-blind, placebo-controlled trial of oral ivermectin alone (12mg once daily for 5 days) or in combination with doxycycline (12mg ivermectin single dose and 200mg stat doxycycline day-1 followed by 100mg 12hrly for next 4 days) compared with placebo among 72 hospitalized patients in Dhaka, Bangladesh. Inclusion criteria were:

age 18-65 years; admitted to hospital within the last 7 days; with either fever (≥37.5 o C); cough or sore throat; and diagnosed positive for SARS-CoV-2 by rRT-PCR. The patients were excluded if they were allergic to or had a potential drug-drug interaction for ivermectin or doxycycline; had chronic illnesses (e.g., ischemic heath disease, heart failure, documented cardiomyopathy, chronic kidney disease, chronic liver disease); received ivermectin and/or doxycycline in the last 7 days; were pregnant or lactating; or participated in any other clinical trial within the last month.

Patients were physically examined for COVID-19 related symptoms and their vital signs (e.g., temperature, blood pressure, pulse rate, oxygen saturation, respiratory rate) were recorded.

Nasopharyngeal swabs were obtained to confirm the presence of SARS-CoV-2 using rRT-PCR on the day of enrolment, and then on day 3, 7, and 14. After day 14, patients were followed-up weekly until found test negative.

Venous blood was collected for blood parameters (CBC, Creatinine, SGPT, RBS) on enrolment and on day 4; chest X-ray and ECG were assessed on enrolment and on day 3. Blood biomarkers Secondary outcomes included patients failing to maintain an SpO2 >93% despite oxygenation and days on oxygen support; duration of hospitalization; and all-cause mortality. Drug safety outcomes recorded were adverse events that occurred during treatment, post treatment, and the discontinuation of the study drug during the trial.

A total of 72 (24 per arm) out of 113 patients who consented were enrolled in the trial. One patient from each of the ivermectin+doxycycline and placebo group and two patients in the 5-day ivermectin arm withdrew their consent during the study due to family obligations and unwillingness to test further. The pretreatment characteristics (demographics, clinical history, comorbidity and laboratory values) were comparable among the three treatment groups. The mean age was 42 years, with 54% being female and ill on average 3.83 days before assessment.

The mean duration of hospitalization after treatment was 9.7 (Confidence interval (CI)= 8.1 -11.0), 10.1 (CI= 8.5 -11.8) and 9.6 (CI= 7.7 -11.7) days in the placebo, ivermectin+doxycycline and Although the study sample was too small (n=72) to make any solid conclusions, the results provide evidence of the potential benefit of the early intervention with the drug ivermectin for the treatment of adult patients diagnosed with mild SARS-CoV-2. First, early intervention promoted faster viral clearance during disease onset which might have prevented significant immune-system involvement and speed recovery. Secondly, early intervention reduced the viral load faster, thus may help block disease transmission in the general population. A larger randomized controlled clinical trial of ivermectin treatment appears to be warranted to validate

COVID-19 Dashboard by the Center for Systems Science and Engineering

Centers for Disease Control and Prevention. Interim Clinical Guidance for Management of Patients with Confirmed 2019 Novel Coronavirus (2019-nCoV) Infection

The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro

Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods

A Case Series of 100 COVID-19 Positive Patients Treated with Combination of Ivermectin and Doxycycline

ICON (Ivermectin in COvid Nineteen) study: use of ivermectin is associated with lower mortality in

We like to express our sincere appreciation and gratitude to the hospital staff who helped to coordinate the trial, to the patients who participated. This research study was funded by Beximco Pharmaceutical Limited (BPL), Bangladesh. icddr,b acknowledges with gratitude the commitment of BPL to its research efforts. icddr,b is also grateful to the Governments of Bangladesh, Canada, Sweden and the UK for providing core/unrestricted support.J o u r n a l P r e -p r o o f